Kingsview Wealth Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-12,491
Closed -$924K 1024
2023
Q4
$924K Buy
12,491
+2,420
+24% +$159K 0.03% 487
2023
Q3
$687K Buy
10,071
+2,580
+34% +$219K 0.02% 538
2023
Q2
$703K Buy
+7,491
New +$584K 0.03% 501
2023
Q1
Sell
-5,154
Closed -$255K 901
2022
Q4
$255K Buy
+5,154
New +$211K 0.01% 721
2022
Q1
Sell
-2,575
Closed -$200K 910
2021
Q4
$200K Sell
2,575
-4,495
-64% -$397K 0.01% 862
2021
Q3
$675K Buy
7,070
+1,405
+25% +$148K 0.03% 477
2021
Q2
$703K Buy
5,665
+2,790
+97% +$333K 0.03% 470
2021
Q1
$381K Hold
2,875
0.02% 582
2020
Q4
$381K Sell
2,875
-5
-0.2% -$605 0.03% 506
2020
Q3
$294K Sell
2,880
-200
-6% -$17.3K 0.03% 480
2020
Q2
$268K Buy
+3,080
New +$246K 0.03% 462

Other funds holding EXAS

Kingsview Wealth Management's EXAS Position: Q1 2024 in Review

Kingsview Wealth Management sold out of Exact Sciences (EXAS) in Q1 2024, closing a stake of 12,491 shares — an estimated $924K sold.

Kingsview Wealth Management first reported a position in EXAS in Q2 2020 and held it in 11 quarters. The position peaked at $924K in Q4 2023. 626 funds tracked by Wall St. Rank hold EXAS as of Q1 2024.

  • Kingsview Wealth Management reported no remaining Exact Sciences position as of Q1 2024 after selling out during the quarter.
  • Kingsview Wealth Management sold 12,491 Exact Sciences shares in Q1 2024, an estimated $924K.
  • Kingsview Wealth Management first reported a position in Exact Sciences in Q2 2020 and held it in 11 quarters.
  • Kingsview Wealth Management's Exact Sciences position peaked at $924K in Q4 2023.
  • 626 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2024.

Based on Kingsview Wealth Management's 13F filing for Q1 2024, filed 9 May 2024.